Therapies that target multiple metabolic products in combination with aberrant signaling pathways, such LKB1-AMPK-mTORC1 and ErbB2-AKT-mTORC2 may be a consideration for the future of targeted cancer treatments, particularly for HER2 resistant trastuzumab-refractory breast cancer [19]. This evidence concerns the gene ERBB2 and breast carcinoma.